CTT Pharma Pursues NIH Grant for Nicotine Strip Research

CTT Pharmaceutical Holdings, Inc., based in Tampa, has submitted a grant proposal to the National Institutes of Health (NIH). This effort seeks to further research and commercialization of the company's dissolvable nicotine strips. The grant proposal complements an existing collaboration with Johns Hopkins University for clinical trials.

CEO Ryan Khouri emphasized that NIH approval would facilitate additional research, potentially leading to the commercialization of their nicotine strips. This proposal emerged after Mr. Khouri's participation in an FDA/NIH session focused on smoking cessation technologies.

CTT Pharma prioritizes its partnership with Johns Hopkins but is also actively seeking NIH support. The company aims to develop products that enhance smoking cessation and reduce related health risks. A decision from the NIH is expected in April 2025.